Expert Opinion on Investigational Drugs This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Investigational agents for autosomal dominant polycystic kidney disease: preclinical and early phase study insights
Expert Opin Investig Drugs. 2024 Apr 15. doi: 10.1080/13543784.2024.2342327. Online ahead of print.ABSTRACTINTRODUCTION: Autosomal Dominant Polycystic Kidney Disease (ADPKD) is the most common inherited kidney condition caused by a single gene mutation. It leads patients to kidney failure in more than 50% of cases by the age of 60, and, given the dominant inheritance, this disease is present in the family history in more than 90% of cases.AREAS COVERED: This review aims to analyze the set of preclinical and early phase studies to provide a general view of the current progress on ADPKD therapeutic options. Articles from Pub...
Source: Expert Opinion on Investigational Drugs - April 15, 2024 Category: Drugs & Pharmacology Authors: Irene Capelli Sarah Lerario Francesca Ciurli Gian Marco Berti Valeria Aiello Michele Provenzano Gaetano Manna Source Type: research

Experimental and new investigational drugs for the treatment of uterine fibroids
Expert Opin Investig Drugs. 2024 Apr 15. doi: 10.1080/13543784.2024.2343786. Online ahead of print.ABSTRACTINTRODUCTION: Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss. Advancements in understand...
Source: Expert Opinion on Investigational Drugs - April 15, 2024 Category: Drugs & Pharmacology Authors: Giulio Evangelisti Simone Ferrero Umberto Perrone Claudio Gustavino Eugenio Volpi Alberto Izzotti Fabio Barra Source Type: research

Sodium/Bile acid co-transporter inhibitors currently in preclinical or early clinical development for the treatment of primary biliary cholangitis
Expert Opin Investig Drugs. 2024 Apr 13. doi: 10.1080/13543784.2024.2343789. Online ahead of print.ABSTRACTINTRODUCTION: Pruritus is common and often undertreated in patients with primary biliary cholangitis (PBC). Existing treatments largely have an aging and low-quality evidence base, and studies included only small numbers of patients. More recent data that has added to our understanding of pruritus treatments has often come from clinical trials where itch was a secondary outcome measure in a trial designed primarily to assess disease modifying agents. This area represents an unmet clinical need in the management of PBC...
Source: Expert Opinion on Investigational Drugs - April 13, 2024 Category: Drugs & Pharmacology Authors: Abhishek Gairola Aaron Wetten Jessica Dyson Source Type: research

Novel carbonic anhydrase inhibitors for the treatment of < em > Helicobacter pylori < /em > infection
Expert Opin Investig Drugs. 2024 Mar 27:1-10. doi: 10.1080/13543784.2024.2334714. Online ahead of print.ABSTRACTINTRODUCTION: Helicobacter pylori, the causative agent of peptic ulcer, gastritis, and gastric cancer encodes two carbonic anhydrases (CA, EC 4.2.1.1) belonging to the α- and β-class (HpCAα/β), which have been validated as antibacterial drug targets. Acetazolamide and ethoxzolamide were also clinically used for the management of peptic ulcer.AREAS COVERED: Sulfonamides were the most investigated HpCAα/β compounds, with several low nanomolar inhibitors identified, some of which also crystallized as adducts w...
Source: Expert Opinion on Investigational Drugs - March 22, 2024 Category: Drugs & Pharmacology Authors: Claudiu T Supuran Source Type: research